Literature DB >> 17516152

The lasso--a novel method for predictive covariate model building in nonlinear mixed effects models.

Jakob Ribbing1, Joakim Nyberg, Ola Caster, E Niclas Jonsson.   

Abstract

Covariate models for population pharmacokinetics and pharmacodynamics are often built with a stepwise covariate modelling procedure (SCM). When analysing a small dataset this method may produce a covariate model that suffers from selection bias and poor predictive performance. The lasso is a method suggested to remedy these problems. It may also be faster than SCM and provide a validation of the covariate model. The aim of this study was to implement the lasso for covariate selection within NONMEM and to compare this method to SCM. In the lasso all covariates must be standardised to have zero mean and standard deviation one. Subsequently, the model containing all potential covariate-parameter relations is fitted with a restriction: the sum of the absolute covariate coefficients must be smaller than a value, t. The restriction will force some coefficients towards zero while the others are estimated with shrinkage. This means in practice that when fitting the model the covariate relations are tested for inclusion at the same time as the included relations are estimated. For a given SCM analysis, the model size depends on the P-value required for selection. In the lasso the model size instead depends on the value of t which can be estimated using cross-validation. The lasso was implemented as an automated tool using PsN. The method was compared to SCM in 16 scenarios with different dataset sizes, number of investigated covariates and starting models for the covariate analysis. Hundred replicate datasets were created by resampling from a PK-dataset consisting of 721 stroke patients. The two methods were compared primarily on the ability to predict external data, estimate their own predictive performance (external validation), and on the computer run-time. In all 16 scenarios the lasso predicted external data better than SCM with any of the studied P-values (5%, 1% and 0.1%), but the benefit was negligible for large datasets. The lasso cross-validation provided a precise and nearly unbiased estimate of the actual prediction error. On a single processor, the lasso was faster than SCM. Further, the lasso could run completely in parallel whereas SCM must run in steps. In conclusion, the lasso is superior to SCM in obtaining a predictive covariate model on a small dataset or on small subgroups (e.g. rare genotype). Run in parallel the lasso could be much faster than SCM. Using cross-validation, the lasso provides a validation of the covariate model and does not require the user to specify a P-value for selection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516152     DOI: 10.1007/s10928-007-9057-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.410


  28 in total

1.  Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

Authors:  K G Kowalski; M M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

3.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

4.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

5.  The Bootstrap, the Jackknife, and the Randomization Test: A Sampling Taxonomy.

Authors:  J L Rodgers
Journal:  Multivariate Behav Res       Date:  1999-10-01       Impact factor: 5.923

6.  Prediction discrepancies for the evaluation of nonlinear mixed-effects models.

Authors:  France Mentré; Sylvie Escolano
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-13       Impact factor: 2.745

7.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

8.  Automated covariate model building within NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

9.  A size standard for pharmacokinetics.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

10.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

View more
  31 in total

Review 1.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

Review 2.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Operating characteristics of stepwise covariate selection in pharmacometric modeling.

Authors:  Malidi Ahamadi; Anna Largajolli; Paul M Diderichsen; Rik de Greef; Thomas Kerbusch; Han Witjes; Akshita Chawla; Casey B Davis; Ferdous Gheyas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-24       Impact factor: 2.745

4.  Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.

Authors:  Elham Haem; Kajsa Harling; Seyyed Mohammad Taghi Ayatollahi; Najaf Zare; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-31       Impact factor: 2.745

5.  Correlates of viral suppression among HIV-infected men who have sex with men and transgender women in Lima, Peru.

Authors:  Katherine M Rich; Javier Valencia Huamaní; Sara N Kiani; Robinson Cabello; Paul Elish; Jorge Florez Arce; Lia N Pizzicato; Jaime Soria; Jeffrey A Wickersham; Jorge Sanchez; Frederick L Altice
Journal:  AIDS Care       Date:  2018-05-30

6.  Combination of radiological and gray level co-occurrence matrix textural features used to distinguish solitary pulmonary nodules by computed tomography.

Authors:  Haifeng Wu; Tao Sun; Jingjing Wang; Xia Li; Wei Wang; Da Huo; Pingxin Lv; Wen He; Keyang Wang; Xiuhua Guo
Journal:  J Digit Imaging       Date:  2013-08       Impact factor: 4.056

7.  CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

Authors:  Mark L McCleland; Kathryn Mesh; Edward Lorenzana; Vivek S Chopra; Ehud Segal; Colin Watanabe; Benjamin Haley; Oleg Mayba; Murat Yaylaoglu; Florian Gnad; Ron Firestein
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

Review 8.  Covariate selection in pharmacometric analyses: a review of methods.

Authors:  Matthew M Hutmacher; Kenneth G Kowalski
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

9.  Concordance between criteria for covariate model building.

Authors:  Stefanie Hennig; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-06       Impact factor: 2.745

10.  Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

Authors:  Camille Couffignal; Olivier Pajot; Cédric Laouénan; Charles Burdet; Arnaud Foucrier; Michel Wolff; Laurence Armand-Lefevre; France Mentré; Laurent Massias
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.